OverviewSuggest Edit

Icagen is a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose-escalation study in healthy volunteers for epilepsy and neuropathic pain; and Senicapoc, which is in Phase I multiple-dose study in healthy volunteers for the treatment of asthma. The Сompany also conducts ongoing drug discovery programs on new therapeutics for pain and inflammatory disorders.
TypePrivate
Founded1992
HQDurham, US
Websiteicagen.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2018)66(-8%)
Revenue (FY, 2018)$13.6 M(-40%)
Cybersecurity ratingAMore

Key People/Management at ICAgen

Timothy Tyson

Timothy Tyson

Chairman of the Board
Paul August

Paul August

Vice President, Biology
Richard Cunningham

Richard Cunningham

CEO and President
Anil Nair

Anil Nair

Vice President, in Silico Drug Discovery
Neil Castle

Neil Castle

Vice President of Research
Doug Krafte

Doug Krafte

Chief Scientific Officer
Show more

ICAgen Office Locations

ICAgen has offices in Durham and Oro Valley
Durham, US (HQ)
4222 Emperor Blvd
Oro Valley, US
2090 E Innovation Park Dr
Show all (2)

ICAgen Financials and Metrics

Summary Metrics

Founding Date

1992

ICAgen total Funding

$6.1 m

ICAgen latest funding size

$1.10 m

Time since last funding

9 years ago

ICAgen investors

ICAgen's latest funding round in May 2011 was reported to be $1.1 m. In total, ICAgen has raised $6.1 m
Show all financial metrics

ICAgen Revenue

ICAgen's revenue was reported to be $13.58 m in FY, 2018
USD

Revenue (Q3, 2019)

3.6m

Net income (Q3, 2019)

(5.7m)

EBIT (Q3, 2019)

(2.0m)

Cash (30-Sept-2019)

2.2m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.9m708.3k541.8k1.6m12.0m22.7m13.6m

Revenue growth, %

(24%)193%655%

Cost of goods sold

656.6k507.8k608.1k1.9m6.4m11.2m

Gross profit

1.2m200.5k(66.3k)(359.9k)5.6m11.5m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

378.6k519.7k6.5m2.3m4.9m2.8m4.1m

Accounts Receivable

59.8k106.0k103.9k967.2k1.3m1.7m2.1m

Prepaid Expenses

17.1k34.1k55.3k357.6k213.4k

Inventories

73.9k62.8k
USDQ2, 2012

Financial Leverage

-0.6 x
Show all financial metrics

ICAgen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

ICAgen Online and Social Media Presence

Embed Graph

ICAgen News and Updates

Icagen enters into Collaboration to Develop and Commercialize Therapy for Neurological Diseases

DURHAM, N.C., Dec. 5, 2018 /PRNewswire/ -- Icagen announced today that they have entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders. The program incorporates Icagen's...

ICAgen Blogs

ICAgen Frequently Asked Questions

  • When was ICAgen founded?

    ICAgen was founded in 1992.

  • Who are ICAgen key executives?

    ICAgen's key executives are Timothy Tyson, Paul August and Richard Cunningham.

  • How many employees does ICAgen have?

    ICAgen has 66 employees.

  • What is ICAgen revenue?

    Latest ICAgen annual revenue is $13.6 m.

  • What is ICAgen revenue per employee?

    Latest ICAgen revenue per employee is $205.8 k.

  • Who are ICAgen competitors?

    Competitors of ICAgen include Evotec, MyoKardia and Otonomy.

  • Where is ICAgen headquarters?

    ICAgen headquarters is located at 4222 Emperor Blvd, Durham.

  • Where are ICAgen offices?

    ICAgen has offices in Durham and Oro Valley.

  • How many offices does ICAgen have?

    ICAgen has 2 offices.